Awards and Rankings

Hogan Lovells named LMG Life Science Regulatory Firm of the Year, Alice Valder Curran and Adam Golden named Regulatory and M&A Attorneys of the Year

Washington, D.C., 25 September 2018 – Hogan Lovells is pleased to announce that it scored three major wins at the sixth annual LMG Life Sciences Awards honoring top-ranking firms and...

Awards and Rankings

Hogan Lovells wins IP Team of the Year at 2018 The Lawyer Awards: The firm is also commended for its litigation, real estate and pro bono work

Hogan Lovells is delighted to announce that the firm has been named as Intellectual Property Team of the Year at the inaugural 2018 The Lawyer Awards.

Blog Post

Italy: Formulation patents may prevent reimbursement of generics… but, are you innovative enough?

The possibility for the patent owner to prevent the reimbursement of medicinal products before expiry of patent protection is still an open issue. While the law covers prohibition of...

Press Releases

UK Supreme Court hands down landmark ruling in favour of Eli Lilly

Following last Friday's (7 July 2017) unusual move of advance publication of the outcome of the case, the UK Supreme Court has today published the reasons for its decision in the...

Press Releases

Hogan Lovells Successfully Acts for Eli Lilly in UK Supreme Court Patent Ruling

In an unusual move, the UK Supreme Court (UKSC) has given its key conclusions in the long running Actavis v Eli Lilly case ahead of giving the full judgment.

Press Releases

Hogan Lovells Partners Named as 2017 BTI Client Service All-Stars

WASHINGTON, 7 February 2017 – Hogan Lovells is pleased to announce that partners Steven Barley, John Booher, Zenas Choi, Robert Hawk, Mitch Lazris, Michael Silver, and Cullen Taylor...

Press Releases

Hogan Lovells Advises Zynerba Pharmaceuticals, Inc. in a $US 50.4 Million Public Offering

NEW YORK, 23 January 2017 – Hogan Lovells is representing Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of...

Press Releases

Hogan Lovells Advises Recro Pharma in Public Offering

NEW YORK, 16 December 2016 – Hogan Lovells represented Recro Pharma, Inc. in a public offering worth approximately US$40 million.

Loading data